(Q34548071)

2 August 2017

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis (English)

1 reference

2 August 2017

1 reference

A J Kivitz

1

1 reference

2 August 2017

S Nayiager

2

1 reference

2 August 2017

T Schimansky

3

1 reference

2 August 2017

A Gimona

4

1 reference

2 August 2017

H J Thurston

5

1 reference

2 August 2017

C Hawkey

6

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Alimentary Pharmacology & Therapeutics

2 August 2017

1 reference

2 August 2017

19

1 reference

2 August 2017

11

1 reference

2 August 2017

1189-1198

1 reference

The prevalence and burden of arthritis

2 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Persistent pain and well-being: a World Health Organization Study in Primary Care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Basic biology and clinical application of specific cyclooxygenase-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Erdheim-Chester disease in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01956.X

10.1111/J.1365-2036.2004.01956.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference